Study disease: Hematologic malignancies including, but not exclusive to, multiple myeloma, acute/chronic leukemia, lymphoma, and myelodysplastic syndrome that has relapsed after allogeneic transplant. Study Rationale: Phase 1 Safety/Dose Finding Study: To determine the safety and maximum tolerated dose of Nivolumab in combination with Tocilizumab. Study Agent Description: Tocilizumab is a monoclonal antibody and immunosuppressant; specifically, tocilizumab is an interleukin-6 (IL-6) receptor antagonist. Nivolumab is a human immunoglobulin IgG4 monoclonal antibody that binds to the PD-1 receptor of T cells blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell proliferation and allowing the immune system to attack the tumor. Number of Subjects: A maximum of 12 patients will be enrolled on this Phase 1 study. Duration of Follow-up: Patients will be followed for up to one year post-treatment for survival and response.
SparkCures ID | 970 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 12 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria
Exclusion Criteria
Please visit the ClinicalTrials.gov page for historical site information.
View Centers